About Advent Life Sciences
Advent Life Sciences is a venture capital firm founded in 2006. It is primarily based out of London, United Kingdom. As of Jan 2026, Advent Life Sciences is an active investor, having invested in 88 companies, with 1 new investment in the last 12 months. It primarily invests in Series A round in United Kingdom based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series C round of Beacon Therapeutics Overall, Advent Life Sciences portfolio has seen 13 IPOs and 33 acquisitions including key companies like Farfetch, Dailymotion and Emergent BioSolutions. A lot of funds co-invest with Advent Life Sciences, with names like Gilde Healthcare sharing a substantial percentage of its portfolio. Advent Life Sciences has team of 17 people including 7 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 5 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Advent Life Sciences' List of Top Investments
Advent Life Sciences has a portfolio of 88 companies. Their most notable investments are in Highlight Therapeutics and Pathwork Diagnostics.Their portfolio spans across United States, United Kingdom, France and 11 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 12 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by Advent Life Sciences:
1. Farfetch
Online retailer offering multi-category fashion products. The product catalog includes apparel, handbags, shoes, watches, jewelry, backpacks, belts, and more for men, women, and kids. In addition, the company also offers pre-owned fashion products. Its mobile application is available for Android and iOS platforms.
Key facts about Farfetch
- Founded Year: 2007
- Location: London (United Kingdom)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $709M
- Employee Count: 3,155 as on Mar 31, 2026
- Investors: HPR Capital, Dragoneer Investment Group and 30 Others
- Latest Funding Round: Post IPO, Apr 27, 2020, $*****
- Highlight: Acquired
2. Dailymotion
Video sharing platform. It is an online video platform that enables users and publishers to upload, watch, and share videos across categories like music, news, sports, entertainment, and live streams.
Key facts about Dailymotion
- Founded Year: 2005
- Location: Paris (France)
- Stage: Acquired
- Total Funding till date: $148M
- Employee Count: 594 as on Jun 30, 2026
- Investors: Atlas Venture, Advent Life Sciences and 12 Others
- Latest Funding Round: Series C, Jun 03, 2015, $*****
- Highlight: Acquired
Developer of vaccines primarily for virus infections. The lead candidate NuThrax, a vaccine in combination with a novel immunostimulatory compound CPG 7909 is for anthrax. Also, has PreviThrax, a vaccine in phase 1 trials for anthrax, VAX161C, a recombinant Hemagglutinin influenza subunit antigen - bacterial flagellin fusion protein H5 influenza vaccine for pandemic influenza and UV-4B, and an antiviral iminosugar in phase 1 trials for dengue virus infections. The company also offers CMO services for both bulk drug substances and sterile injectable drug products.
Key facts about Emergent BioSolutions
- Founded Year: 1998
- Location: Gaithersburg (United States)
- Annual Revenue: $1B+ as on Dec 31, 2024
- Stage: Public
- Employee Count: 1,366 as on Jun 30, 2026
- Investors: Advent Life Sciences, Orbimed and 12 Others
- Latest Funding Round: Grant (prize money), Sep 01, 2022, $*****
- Highlight: Public
_1585696644349.jpg?format=webp&height=120&width=120){kind=logo}
Developer of targeted protein degradation medicines for treating pathogenic proteins. These therapeutics function by triggering the destruction and removal of specific proteins associated with disease progression. The technology utilizes rationally designed molecules to consolidate performance characteristics of traditional degradation approaches. This method enables the targeting of a wider scope of tissues and indications than conventional protein degradation techniques.
Key facts about Amphista Therapeutics
- Founded Year: 2017
- Location: Cambridge (United Kingdom)
- Annual Revenue: £10M - £50M as on Dec 31, 2024
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $60.5M
- Employee Count: 46 as on Jun 30, 2026
- Investors: Gilde Healthcare, Advent Life Sciences and 10 Others
- Latest Funding Round: Series B, Dec 13, 2022, $*****
- Highlight: Editors' Pick
5. Axonics
Developer of a device to control urinary and bowel movements. The Axonics System is a small portable device made of a neurostimulator and a patented helical-tined design for lead migration and a GUI-based tablet for clinician programming. The device is implanted in the sacral region and uses sacral neuromodulation technology that provides regular current-based stimulation to control urinary and bowel movements.
Key facts about Axonics
- Founded Year: 2013
- Location: Irvine (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2023
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $143M
- Employee Count: 301 as on Jun 30, 2026
- Investors: Gilde Healthcare, Advent Life Sciences and 9 Others
- Latest Funding Round: Conventional Debt, Apr 03, 2018, $*****
- Highlight: Acquired
Advent Life Sciences' Year-on-Year Investment Trends
Advent Life Sciences has invested in 88 companies over the last 27 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 3 investments, while as of Jan 2026, it has made 1 investment in this year. Its most recent first time investment was in Cyted and most recent follow-on round was in Beacon Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 1 | 1 |
2025 | 3 | 0 | 3 |
2024 | 2 | 5 | 7 |
2023 | 0 | 1 | 1 |
2022 | 4 | 6 | 10 |
2021 | 2 | 4 | 6 |
2020 | 4 | 2 | 6 |
2019 | 3 | 3 | 6 |
2018 | 3 | 2 | 5 |
2017 | 2 | 4 | 6 |
Advent Life Sciences' Investments by Stage
Advent Life Sciences has made 28 investments in Series A stage with an average round size of $18.3M, 18 investments in Series B stage with an average round size of $44.6M and 6 investments in Seed stage with an average round size of $9.16M.Stage of entry | No. of Investments |
|---|---|
Series A | 28 |
Series B | 18 |
Seed | 6 |
Series C | 6 |
Series D | 3 |
Others | 3 |
Note: We have considered here, only first round of investments
Advent Life Sciences' Investments by Sector
Advent Life Sciences has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, High Tech, HealthTech and Sustainability Tech. Notably, it has invested in 75 Tech companies, 58 Enterprise (B2B) companies, 24 Software companies and at least 15 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 46 |
Enterprise Applications | 10 |
High Tech | 8 |
HealthTech | 5 |
Sustainability Tech | 5 |
Others | 24 |
Note: We have considered here, only first round of investments
Advent Life Sciences' Investments by Geography
Advent Life Sciences has made most investments in United Kingdom (28), followed by United States where it has made 24 investments.Country | No. of Investments |
|---|---|
United Kingdom | 28 |
United States | 24 |
France | 3 |
Switzerland | 3 |
Belgium | 1 |
Others | 7 |
Note: We have considered here, only first round of investments
Advent Life Sciences' recent investments
Advent Life Sciences has made 1 investments in 2026 so far - Beacon Therapeutics.Here are the most recent investments by Advent Life Sciences:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 08, 2026 | United States | Series C | 8046 | [+4] | |
Sep 01, 2025 | United Kingdom | Series B | 3315 | [+3] | |
Apr 16, 2025 | United States | Series C | 2971 | ||
Jan 08, 2025 | United States | Series A | 1155 | [+2] | |
Oct 24, 2024 | United Kingdom | Seed | 2595 | [+8] |
IPOs and Publicly Listed companies in Advent Life Sciences' Portfolio
13 of Advent Life Sciences' portfolio companies have become public. Aura Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2021 at marketcap of $398M and Acutus Medical got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $470M.Here are Advent Life Sciences' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 29, 2021 | Mar 05, 2015 | Series B | 6566 | |
Aug 07, 2020 | Aug 20, 2013 | Series B | 9482 | |
May 25, 2018 | Mar 02, 2018 | Series B | 1074 | |
Feb 26, 2016 | - | - | 4340 | |
Apr 27, 2015 | Oct 15, 2009 | Series A | 9374 |
Acquired companies in Advent Life Sciences' Portfolio
33 companies from Advent Life Sciences' portfolio have been acquired. The most recent acquisition was Centessa Pharmaceuticals in Mar 2026 by Lilly for $*****.Here are Advent Life Sciences' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 31, 2026 | - | - | 7056 | |
Oct 17, 2025 | Feb 17, 2022 | Series B | 7816 | |
Jan 08, 2024 | Dec 18, 2015 | Series B | 4193 | |
Dec 18, 2023 | Jan 16, 2012 | Series B | 1317 | |
Aug 04, 2022 | Apr 15, 2019 | Series A | 6263 |
Team profile of Advent Life Sciences
Advent Life Sciences has a team of 17 members including 7 Partners, 5 Venture Partners and 2 Principals located in United Kingdom, United States and 2 more locations. Advent Life Sciences' team sits on the board of 2 companies.Here is a list of top team members in Advent Life Sciences:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Cambridge | - | ||
Partner | London | - | ||
Partner | Cambridge | - | ||
Partner | Cambridge | |||
Partner | London | |||
Partner | London | - | ||
Partner | India | - | - | |
Venture Partner | Princeton | - | ||
Venture Partner | Westwood | - | ||
Venture Partner | Boston | - | ||
Venture Partner | United Kingdom | - | - |
Co-investors of Advent Life Sciences
Over the past 27 years, 358 investors have co-invested in Advent Life Sciences's portfolio companies. This includes funds and angels.
- Invested before Advent Life Sciences: Index Ventures, 3i Group and 70 others have invested in rounds before Advent Life Sciences. There are 4 companies where Index Ventures has invested before Advent Life Sciences and 2 companies where 3i Group has invested before Advent Life Sciences.
- Top Co-investors of Advent Life Sciences: 133 investors entered a company along with Advent Life Sciences. These include investors like Gilde Healthcare (4 companies).
- Invested after Advent Life Sciences: A total of 153 investors have invested in Advent Life Sciences's portfolio after their investments. Top Investors include Novartis Venture Fund (4 companies), Columbus Venture Partners (4 companies) and Forbion (3 companies).
Recent News related to Advent Life Sciences
•
Argá Medtech Announces First Enrollments in COHERENT-AF IDE Clinical TrialPR Newswire•Sep 19, 2025•Advent Life Sciences
•
UK diagnostics firm Cyted Health secures $44m series BTech in Asia•Sep 02, 2025•Cyted, Morningside, EQT, British Business Bank and 3 others
•
•
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Pharmaceutical Technology•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, Advent Life Sciences, Novo Holdings and 7 others
•
Glycomine Secures $115M Series C Funding for Rare Disease TreatmentBioSpace•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, Advent Life Sciences, Novo Holdings and 7 others
•
Glycomine Secures $115M in Series C FundingFinSMEs•Apr 16, 2025•Glycomine, CTI Life Sciences Fund, abrdn, Advent Life Sciences and 8 others
•
Relief Cardiovascular Raises $12M in Series A FinancingFinSMEs•Jan 08, 2025•Relief Cardiovascular, Broadview Ventures, Advent Life Sciences, Pacific Health Ventures and 1 other
•
Moximed Closes $61 Million Series Dsvdaily.com•Aug 20, 2024•Moximed, Elevage Medical Technologies, Patient Square Capital, Cormorant Capital and 7 others
•
Moximed secures $91m to advance MISHA knee systemMedicalDeviceNetwork•Aug 14, 2024•Moximed, Elevage Medical Technologies, Warren Point Capital, New Enterprise Associates and 8 others
•
Moximed Completes Closing of Series D FinancingOrthoworld•Aug 13, 2024•Moximed, Elevage Medical Technologies, Cormorant Capital, Warren Point Capital and 12 others
